---
schema_version: "secwatch.filing_event.v1"
accession: "0001079973-22-000579"
form_type: "8-K"
ticker: "LCTC"
cik: "0001493137"
company_name: "Lifeloc Technologies, Inc"
filed_at: "2022-05-12T23:59:59+00:00"
generated_at: "2026-06-25T18:09:01.749936+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lifeloc Q1 2022 net loss $145K vs profit $403K in Q1 2021, revenue up 19% to $2.161M

## Summary
- Net loss of $145K ($0.06 diluted EPS) vs. net profit of $403K ($0.16 diluted EPS) in Q1 2021, which included a $465K PPP loan forgiveness gain.
- Revenue $2.161M, up 19% YoY, driven by demand recovery and new product adoption.
- R&D investment increased to develop SpinDx drug testing platform; expects initial SpinDx sales this year.
- New LX9 and LT7 devices driving strong sales growth; L-series products gaining market traction.

## SEC filing metadata
- accession: 0001079973-22-000579
- form_type: 8-K
- ticker: LCTC
- cik: 0001493137
- company_name: Lifeloc Technologies, Inc
- filed_at: 2022-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1493137/000107997322000579/0001079973-22-000579-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1493137/000107997322000579/lclc_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001079973-22-000579
- JSON: https://secwatch.observer/filing/0001079973-22-000579.json
- Plain text: https://secwatch.observer/filing/0001079973-22-000579.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.